Celon has made robust investments over the last two years to build its world-class research centre to augment its growth plans in the Global Generics segment. We are currently developing a number of generic products through a combination of internal and collaborative programs.
Our Global Generics R&D strategy focuses on the following product development areas:
- Off-patent drugs that are difficult to develop or manufacture, or that complement or broaden our existing product lines
- The development of Novel drug delivery technologies and the application of these technologies to proprietary drug forms.
- Using in-house technologies to develop new products.